Thiazolidinediones are adjunctive therapies for diabetes mellitus (type 2) and related diseases.
One of the members of the advisory panel set up to discuss the future of the diabetes pill Avandia says it should be removed from the market because it is too risky and offers no advantage over other alternatives.
A type 2 diabetes drug taken orally and in widespread use for more than a decade has been found to have distinct advantages over nine other, mostly newer medications used to control the chronic disease, according to a study by researchers at Johns Hopkins.
After screening hundreds of compounds for their effects on fat development, researchers have discovered that an ingredient found in some plants fights diabetes in mice without some of the side effects attributed to other antidiabetes drugs.
A medication given to diabetics to improve their body's sensitivity to insulin also appears to slow the thickening of their artery walls, according to a study posted online by JAMA: The Journal of the American Medical Association.
A drug commonly used to increase the body's sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine.
The Food and Drug Administration (FDA) in the U.S. has granted approval for a new drug to treat adults with type 2 diabetes.
Researchers at an Alzheimer's Conference in Spain have come up with more information on the disease and just who amongst the population is most likely to get it.
Diabetics who were prescribed newer medications to control their illness were more likely to take these drugs as instructed than were other patients who were prescribed drugs that have been on the market for several decades.
Thiazolidinediones (TZD's) are drugs commonly prescribed to patients with type 2 diabetes, the most common form of diabetes. Current U.S. Food and Drug Administration-approved agents are known as Actos (pioglitazone) and Avandia (rosiglitazone).
For the first time, scientists have discovered how C-reactive protein, or CRP, is able to access endothelial cells. The UC Davis researchers' findings will be published in the July issue of Arteriosclerosis, Thrombosis, and Vascular Biology, one of the American Heart Association's leading journals.
A drug, which reduces insulin resistance and also may have anti-inflammatory and other effects on blood vessels, lowered cardiovascular risk factors in patients with diabetes more than another diabetes medicine, even though both drugs improved blood sugar control equally, according to a new study (PDF) in the June 21, 2005, issue of the Journal of the American College of Cardiology.
In related discoveries with far-reaching implications for treating diabetes and understanding hypertension, University of Utah researchers have learned why thiazolidinediones (TZDs), a major anti-diabetes drug, cause edema and also have found a new pathway critical to fluid metabolism. Identification of this pathway may help understand fundamental mechanisms of blood pressure control.
Type 2 diabetes may be significantly delayed or prevented through medication that takes the load off of the body's delicate insulin-producing cells, according to a study released today by researchers at the Keck School of Medicine of the University of Southern California.
In people with signs of metabolic syndrome, including high blood pressure, high triglycerides, high cholesterol, elevated blood glucose and obesity, physical activity appears to reduce a marker for inflammation which has been linked to heart disease
Rosiglitazone, a drug taken to help improve blood sugar levels, also helps boost the effectiveness of a treatment for opening clogged arteries, according to a study in the November issue of Diabetes Care.
New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.
A clinical study comparing three treatments of type 2 diabetes in children and teens has begun in 12 medical centers and their affiliated sites around the country, HHS Secretary Tommy G. Thompson announced today.